Breaking the Silence, Lighting the Dark: Innovations in Usher Syndrome Treatment

Dhruva Singu

Abstract

Usher Syndrome is an autosomal recessive disorder and the leading cause of combined deafness and blindness worldwide. It affects 25,000 people in the United States and 400,000 people worldwide (Usher Syndrome Coalition; U.S. Department of Health and Human Services). It is characterized by congenital hearing loss and progressive vision impairment due to retinitis pigmentosa. The condition is caused by mutations in several genes, such as MYO7A, USH2A, and CLRN1 (U.S. National Library of Medicine, *MYO7A Gene*; U.S. National Library of Medicine, *USH2A Gene*; U.S. National Library of Medicine, *CLRN1 Gene*). Conventional treatments, such as cochlear implants, low-vision aids, and speech therapy, often help mitigate the symptoms but do not repair the underlying genetic basis of the disease. In this article, the potential of gene therapy as a breakthrough treatment for Usher Syndrome will be assessed. The in vivo gene therapy approach enables the introduction of corrective genetic materials into Usher Syndrome patients using viral or non-viral vectors. Advances in gene therapy, such as dual Adeno-Associated Virus (AAV), allowed for the delivery of larger genes such as MYO7A, allowing for partial function restoration in preclinical models. Antisense oligonucleotides (ASOs), especially QR-421a, have shown potential in manipulating USH2A mutations with RNA splicing, with encouraging results in early-phase clinical trials. Human trials for this therapy approach, including the LUCE-1 Phase 1/2 and LUNA Phase 2b, are currently proving safety and efficacy. Although challenges such as immune response, gene size limitations, and delivery accuracy persist, advancements in vector design engineering, CRISPR editing, and precision medicine provide hope for curative therapies. Future treatments can benefit from combining gene therapy with stem cell regeneration and neuroprotective pharmacology to achieve optimal long-term outcomes. Overall, gene therapy remains a promising approach to not only managing but also reversing the symptoms of Usher Syndrome, and offers a more personalized and effective treatment for Usher Syndrome.

Introduction

Usher Syndrome is the leading genetic cause of combined hearing and vision loss in the world, accounting for nearly 50% of cases of deaf-blindness. Although it is considered a rare disorder, it affects about 4 to 17 people per thousand worldwide (U.S. Department of Health and Human Services). This dual-sensory disorder follows an autosomal recessive inheritance pattern, which means an individual has to inherit two copies of the mutated recessive gene from each parent to express the condition (U.S. National Library of Medicine). Usher Syndrome is caused by numerous mutations in the genes essential to the operation of the inner ear and retinal cells. A couple of these genes are *MYO7A, USH1C, CDH23, USH2A,* and *CLRN1.* These genes provide the instructions for making proteins involved in hearing, balance, and vision. A mutation is a permanent change to a gene that has the potential to disrupt its function, ultimately leading to a malfunctioning protein and potentially causing disease symptoms. Usher's symptoms can

progressively worsen over time, beginning with hearing loss, followed by vision loss with retinitis pigmentosa, a degenerative eye disease that causes night blindness and tunnel vision(U.S. Department of Health and Human Services; U.S. National Library of Medicine). According to the Usher Syndrome Coalition, a reputable organization focusing on Usher Syndrome research, there are three types of Usher Syndrome, all of which vary in the severity and the onset of the symptoms (Usher Syndrome Coalition). Type 1 is the most severe, with profound deafness from birth, balance problems, and early-onset vision loss. Type 2 presents with moderate-to-severe hearing loss from birth and visual symptoms beginning in adolescence, while Type 3 involves progressive hearing and vision loss starting in adolescence or adulthood (Usher Syndrome Coalition). The disease will severely impact a person's ability to communicate and navigate through their environment effectively. Across all types, hearing loss occurs first, so patients often purchase cochlear implants or other types of hearing aids. As per the visual aspect of the disease, patients usually utilize low-vision aids or get orientation and mobility training, as this can help them read better and get around their surroundings better, respectively. However, these options are simply medical interventions that can alleviate the symptoms of the disease, but don't address the underlying issue (U.S. Department of Health and Human Services; Usher Syndrome Coalition).

Given the lack of success in current treatments' ability to address the underlying disease, researchers have been exploring gene therapy as a potential solution to treat Usher Syndrome (Mayo Foundation for Medical Education and Research; Genome.gov). Gene therapy is a medical intervention that focuses on treating a genetic disease by modifying the mutated gene or transferring genetic material to correct the mutation (Genome.gov). Gene therapy aims to repair the underlying cause of a genetic condition rather than simply mitigating the symptoms. There are two main types of gene therapy: *in vivo* gene therapy and *ex vivo* gene therapy. *In vivo* gene therapy is when the therapeutic gene is delivered directly into a patient's body, either through targeting a specific anatomical site or circulating it throughout the patient's body to reach organs such as the brain, spinal cord, liver, muscles, or lungs (Cantore et al.). Conversely, *ex vivo* gene therapy is an approach in which cells are collected from a patient and then modified outside of the lab by using a virus that inserts the therapeutic gene into the body while returning altered tissues to the patient (Genome.gov).

The primary technique currently being explored to treat Usher Syndrome is *in vivo* gene therapy (Cantore et al.; Williams et al.). In *in vivo* gene therapy, there are viral and non-viral methods of delivery. Using viral delivery, genetic material can be delivered directly to patients' cells using genetically modified virus vectors. On the contrary, in non-viral delivery, various compounds or physical methods can be used to deliver these materials into the cells (Genome.gov; Cantore et al.). Both of these methods can be used to deliver gene therapy treatment in Usher Syndrome. In this review paper, Usher Syndrome will be defined, and the three types of Usher Syndrome will be discussed, along with the symptoms and genes associated with each type. The conventional treatment approaches for Usher Syndrome will be evaluated, including their lack of effectiveness and other disadvantages. Lastly, current gene therapy treatments for Usher Syndrome and their promise as a new solution for eradicating the disease will be examined.

Usher Syndrome

Usher Syndrome is an autosomal recessive disorder characterized by congenital (present from birth) hearing loss and progressive vision loss caused by Retinitis Pigmentosa (U.S. Department of Health and Human Services). The condition begins with hearing loss from birth, and later causes impaired night vision due to rod cell degeneration, which can lead to tunnel vision and blindness later in life. However, the timing of the onset of these symptoms depends on the type of Usher Syndrome one may have (U.S. Department of Health and Human Services).

There are three main types of Usher Syndrome (Table 1): type 1, type 2, and type 3. Type 1 Usher Syndrome patients usually have profound hearing loss from birth, progressive vision loss due to retinitis pigmentosa, night vision loss by age 10, and improper balance. Type 1 Usher Syndrome is associated with mutations in the following genes: *MYO7A, USH1C, CDH23,* and *PCDH15.* These genes primarily code for functions relating to inner ear hair cells and cells in the retina (U.S. National Library of Medicine). Type 2 Usher Syndrome patients usually have moderate to severe hearing loss from birth, progressive vision loss, night blindness by their teenage years, and normal balance. Type 2 Usher Syndrome is caused by a mutation in the *USH2A* gene. This gene codes for the Usherin protein, which maintains the structure and function of photoreceptor cells in the retina and hair cells in the cochlea. Type 3 Usher Syndrome is associated with hearing loss from childhood, night vision loss in teenage years, and maintaining a normal balance (U.S. National Library of Medicine). Type 3 Usher Syndrome is associated with the *CLRN1* gene. This is the gene responsible for clarin-1 protein, which is involved in the function of hair cells in the cochlea and photoreceptors in the retina. (U.S. National Library of Medicine). Around twenty-five thousand people across the United States suffer from Usher Syndrome, and around four hundred thousand people worldwide suffer from the condition (Usher Syndrome Coalition).

Since Usher Syndrome is both clinically and genetically heterogeneous, the disease can be challenging to diagnose. This is because there are a variety of overlapping symptoms, various onsets for the symptoms, and the progression rate can complicate the clinical diagnosis. In addition, since there are numerous Usher-related genes, genetic diagnosis is more complicated. However, an accurate diagnosis and identification of the causal gene is necessary for the specific prognosis and potential need for genetic therapy interventions. Thus, getting diagnosed earlier and more accurately is key to implementing proper disease intervention, so the quality of life of individuals will increase (Fuster-García et al.).

Table 1: Types of Usher Syndrome, symptoms, and genes involved

Types of Usher Syndrome	Symptoms			Linked Genes	Gene Function	Citations
	Hearing Loss	Vision Loss	Balance			
Type 1	Profound hearing loss at birth	Night vision loss by ~age 10, progressive vision loss	Normal balance	*MYO7A* *USH1C* *CDH23* *PCDH15*	Function Related to Inner Ear Hair Cells	(U.S. National Library of Medicine, *MYO7A Gene*; Fuster-García et al..)
Type 2	Moderate to severe hearing loss from birth	Night blindness in teenage years, progressive vision loss	Normal balance	*USH2A*	Codes for Usherin Protein, which maintains the structure or function of photorece-ptor cells in the retina and hair cells in the cochlea	(U.S. National Library of Medicine, *USH2A Gene*; Fuster-García et al..)(U.S. National Library of Medicine, *CLRN1 Gene*; Fuster-García et al..)
Type 3	Progressive hearing loss in childhood	Night vision loss in teenage years, progressive vision loss	Normal balance	*CLRN1*	Codes for clarin-1 protein, important for cochlear hair cells and retinal photorece-ptor cell functioning	(U.S. National Library of Medicine, *CLRN1 Gene*; Fuster-García et al..)

Conventional Treatment

Usher Syndrome currently lacks a definitive cure, making symptom management the cornerstone of patient care and necessitating a multidisciplinary approach to enhance patients' quality of life (U.S. Department of Health and Human Services). Most of the management strategies for Usher Syndrome involve addressing the auditory and visual impairments caused by the disease. For hearing loss, the primary intervention is the use of hearing aids or cochlear implants. Hearing aids are designed to amplify sound and benefit individuals with mild to moderate hearing loss. Cochlear implants are electronic devices that bypass the ear and directly stimulate the auditory nerve, which gives a sense of sound to individuals with severe to profound hearing loss (U.S. Department of Health and Human Services; U.S. Department of Health and Human Services). Next, many patients diagnosed with Usher Syndrome will undergo speech or language therapy. This is often needed because hearing aids and cochlear implants emit sounds that differ from natural hearing, which makes it difficult for patients, especially children, to develop natural communication skills (U.S. Department of Health and Human Services).

Visual impairments can be managed through low-vision aids, such as magnifiers and screen readers, which assist individuals in performing daily tasks. These devices are meant to help patients with deteriorating vision, often due to Retinitis Pigmentosa. Orientation and mobility training help those with vision loss navigate their environments safely, often with the help of a walking stick to detect objects in their surroundings, or with the help of a service animal (U.S. Department of Health and Human Services; American Foundation for the Blind). In addition, recent studies have suggested that Vitamin A supplementation may help slow the progression of retinitis pigmentosa; however, its clinical efficacy remains inconclusive due to limited long-term data and potential toxicity risks, such as liver damage and teratogenicity (Berson et al.; Wang, Qi, et al.). However, the efficiency of the supplement at slowing down the growth of retinitis pigmentosa is still under research.

While symptom management treatments can improve the quality of life, they do not address the underlying genetic causes of Usher Syndrome. Further, hearing aids and cochlear implants do not restore normal hearing and are not effective for all cases of Usher Syndrome. Similarly, low vision aids and mobility training do not restore one's eyesight or stop the progression of the vision loss. When these interventions are used together, they greatly enhance an individual's quality of life, but they will not prevent or pause the progression of the disease (U.S. Department of Health and Human Services; U.S. Department of Health and Human Services).

What is Gene Therapy?

Gene therapy is a revolutionary medical approach that focuses on treating or preventing genetic diseases by introducing or repairing genetic material into a patient's cells (U.S. National Library of Medicine). As discussed earlier, gene therapy allows for the delivery of genetic materials that can correct mutations in Usher Syndrome via either *in vivo* or *ex vivo* techniques. In Usher

Syndrome, the typical approach is to try to use *in vivo* methods to avoid the difficulties that can arise in extracting the cells in the eye and the inner ear (Canver).

Several vectors, which refer to carriers that deliver working genes to target cells, have been developed for *in vivo gene therapy.* The most common vectors are viral vectors, such as Adeno-Associated Viruses (AAVs) and lentiviruses (Hinderer et al.). AAVs are non-pathogenic and are known for their immunogenicity and long-term genetic expression (Aartsma-Rus & Van Ommen). These vectors tend to be naturally occurring viruses that have been engineered to deliver only genetic materials of interest, so they cannot integrate into the host DNA. This means that they cannot cause harm to a patient's body. AAVs usually enter the cell through endocytosis, travel to the nucleus, and remain as episomal DNA, which allows for stable therapeutic gene expression without integration into the host genome (Sinn et al.). Lentiviruses, conversely, directly integrate into the genome and primarily target cells that divide slowly, such as retinal cells (Ginn et al.). Non-viral vectors such as liposomes and nanoparticles offer an alternative, delivering genes through chemical or physical methods and reducing immune risks, although they generally have lower efficiency (Hashimoto et al.).

As tabulated in Table 2, gene replacement involves delivering a functional copy of the mutated gene, such as *MYO7A* or *USH2A* (Williams et al.; Sinn et al.). Gene editing tools like CRISPR-Cas9 allow precise correction of mutations by cutting the DNA and allowing natural repair mechanisms to correct the mutations (Gerard et al.). Antisense oligonucleotides (ASOs) bind to mRNA to alter splicing or block faulty protein production, and are particularly useful for helping treat mutations in larger genes like *USH2A* (Aartsma-Rus & Van Ommen). Exon skipping is an ASO-related method that enables cells to skip faulty exons during mRNA processing, which produces partially functional proteins (Scalabrino et al.). While these approaches are promising, they face challenges like: immune responses to vectors; limited packaging capacity, especially for larger genes; and age-related decline in target cell receptivity (Williams et al.; Sinn et al.; Lau et al.). Despite these limitations, gene therapy remains a promising avenue for treating the root genetic causes of Usher Syndrome and is actively being studied in various preclinical and clinical trials (Jinek et al.; Lau et al.).

Table 2: Different gene therapy approaches for the treatment of Usher Syndrome

Gene Therapy Approach	Mechanicism	Genes Targetted	Advantages	Limitations and Challenges	Citations
Gene replacement	Delivers a functional copy of the mutated gene to restore normal protein production	*MYO7A, USH2A*	Addresses root genetic defect; potential for long-term effect	Limited by vector packaging capacity (*USH2A)*	(Williams et al.)
Gene editing (CRISPR-Cas9)	Cuts DNA at the mutation site, allowing natural repair to correct the error	Any Usher linked gene	High Precision; Permanent correction	Potential off-target effect; delivery challenges	(Jinek et al.)
Antisense oligonucleotides (ASOs)	Bind to mRNA to modify splicing or block faulty protein translation	*USH2A* and other large genes	Effective for large genes that cannot fit into AAVs; non-permanent.	Requires repeated administration, limited to certain mutation types	(Gerard et al.)
Exon skipping (ASO-related)	Skips faulty exons during mRNA processing to produce partially functional proteins	*USH2A*	Restores parietal protein function. Avoids harmful exons	May not entirely restore protein function; repeat dosing needed	(Aartsma-Rus & Van Ommen)

Gene Therapy as a Treatment Solution for Usher Syndrome

Advancements in gene therapy offer promising avenues for treating Usher Syndrome. There are a large number of approaches being proposed for the correction and replacement of mutated genes associated with the condition.

AAV vectors have been widely used in gene therapy to deliver functional copies of defective genes to affected cells. Since the mutated genes, including *MYO7A* and *USH2A,* in Usher Syndrome are quite large, scientists are working on a new delivery system called the dual AAV vector system that splits the gene into two parts, allowing for the delivery of a larger package. In a recent mouse model of Usher Syndrome 1B, 2023 Lau et. al. used a dual AAV8(Y733F) system to split the large *MYO7A* gene, which is approximately 6.7 kb, into two parts, which were combined with cells of shaker-1 mice, a model of USH1B, to restore *MYO7A* expression.

In the study, the dual AAV8(Y733F) system led to rescued vestibular hair cell structure, increased vestibular sensory-evoked potentials, and reduced circling behavior in shaker-1 mice, although hearing sensitivity was not fully recovered (Zallocchi et al., Ferla et al.). In a different study, 2023 Ferla et al.. applied a similar dual AAV approach in a non-human primate model of Usher Syndrome Type 1B, successfully delivering MYO7A and achieving long-lasting restoration of retinal function (AAVantgarde). Together, these studies demonstrate the potential of dual AAV-mediated MYO7A delivery to restore sensory function across both auditory-vestibular and visual systems (Figure 1).



Figure 1: *Dual AAV vectors allow for the delivery of the large MYO7A gene, restoring retinal function and vision in inherited retinal disease. The MYO7A gene is split into two fragments carried by separate AAV vectors. Inside the cells, the fragments can reassemble to create a full-length and functional gene. Made via BioRender*

These animal models pave the way for the translation of this therapy into human clinical trials.

The LUCE-1 is a brand-new first-in-human approach that is in its first phase of two. This is an open-label, dose-escalation study of AAVB-081, a dual-AAV gene therapy designed to target MYO7A mutations, which are the genetic basis of Usher Syndrome Type 1B (USH1B). In this specific approach, two AAV-8 vectors are each carrying one-half of the 6.7 kb *MYO7A* transgene. The two AAV8 vectors are injected subretinally, where they recombine within retinal cells to express a functional MYO7A protein (Stansfield; Foundation Fighting Blindness). The study is being conducted at the University Hospital of Campania and includes 15 adult participants between the ages of 18 and 50 who are diagnosed with Usher Type 1B retinitis pigmentosa. Participants are divided into three escalating dose cohorts and are being followed for 61 months. The primary endpoint checks for safety and tolerability, especially dose-limiting toxicities and adverse events. Secondary endpoints include changes from the baseline in visual function, like microperimetry and static perimetry. As of December 2024, the two patients receiving a low dose showed only mild self-resolving adverse events, and their visual acuity returned to baseline within two weeks (Foundation Fighting Blindness). In May of 2025, data from 8 patients, including 3 patients from the mid-dose cohort, and a six-month efficacy outcome on the first patient who received a dose, there were no major treatment-related events; most notably, the first patient showed improvement of more than one line in terms of visual acuity along with other positive trends in various functional visual metrics (Stansfield; Foundation Fighting Blindness).

Another current clinical trial is the LUNA Phase 2b trial, a randomized, double-masked, sham-controlled, two-year study evaluating ultevursen, an antisense RNA oligonucleotide designed to mask exon 13 mutations in the *USH2A* gene, thereby restoring correct USH2A protein expression in retinal cells. This trial has 81 participants ranging from eight-year-old children to adults with retinitis pigmentosa due to biallelic *USH2A* mutations, including one in exon 13 (ClinicalTrials.gov; Dulla et al.). Patients are randomized in a two-to-one ratio to receive intravitreal injections of ultevursen at baseline, 6, 12, and 18 months, while the control group is undergoing sham procedures (ClinicalTrials.gov; Dulla et al.). The primary outcomes assess safety and tolerability, while the secondary outcomes evaluate changes in visual acuity, retinal sensitivity, and retinal structure (ClinicalTrials.gov; Dulla et al.). Dosing for this study began in December of 2024, and the first patient was treated in Dallas, Texas (ClinicalTrials.gov). Nonetheless, several challenges to gene therapy still remain. The efficiency of dual AAV vector systems can be limited by the need for both vectors to enter the same cell or build up the same gene (Zallocchi et al..; Ferla et al..; Foundation Fighting Blindness). In addition to this, immunogenicity poses a big challenge to the effectiveness of the therapy, as an immune response can mitigate the effectiveness of the therapy (Ferla et al..; Foundation Fighting Blindness; ProQR Therapeutics). To mitigate these issues, vector engineering can be used to reduce immunogenicity and the use of immunosuppressive treatments during therapy (ProQR Therapeutics). Along with this, the dynamic nature of hair cells in the inner ear may affect the long-term efficacy of gene therapy, which requires further research into proper delivery methods and timing (Zallocchi et al..; Ferla et al..; ProQR Therapeutics).

In addition to replacing defective genes by delivery of cDNA copies of functional genes, another approach involves delivery of antisense oligonucleotides (AONs), short synthetic DNA and RNA fragments that can bind and modify RNA during splicing in order to repair mutations in genes like the gene *USH2A (*ProQR Therapeutics). For example, in a humanized zebrafish model of Usher Syndrome, 2018 Slijkerman et. al. used AONs targeting the deep-intronic c. 7595-2144A>G mutation in *USH2A* to partially correct the aberrant *USH2A* (Trapani et al.). In a different study by Dulla et. al., as shown in Figure 2, the proposed method used AON (QR-421a) allows for the skipping of exon 13, which normally carries pathogenic mutations (Muhuri et al.).



Figure 2: *Exon skipping via Antisense Oligonucleotides (ASOs) like QR-421a corrects defective USH2A splicing, by removing exon 13, allowing for the production of a partially functional Usherin protein, restoring vision. Made via BioRender.*

The proposed AON approach established that AON showed long-term effects in retinal expression in zebrafish and mouse models (Muhuri et al.). QR-421a is now being assessed in a phase 1/2 clinical trial for *USH2A*-related retinitis pigmentosa (Chen et al.). In the Phase 1/2 Stellar trial, in 20 patients (all over 46 years old), including both Usher Syndrome and non-syndromic retinitis pigmentosa, it was shown that one intravitreal dose of QR-421a can potentially stabilize or even improve the visual acuity and field measures over 48-96 weeks, with no serious adverse events (Slijkerman et al.). The subsequent Celeste and Sirius pivotal trials are now enrolling more cohorts to confirm the efficacy over two years (Slijkerman et al.).

CRISPR-based editing techniques and newer RNA-targeted systems like Cas13a have been demonstrating precise gene correction and phenotypic rescue in cellular and animal models

(Slijkerman et al..; Garanto; Dalkara et al.). While these tools are still emerging, they promise a one-time, mutation-specific solution that can avoid some ethical concerns and viral payload conditions inherent to DNA-level editing (Garanto; Dalkara et al.).

Thus, combining gene replacement via dual-AAV or lentiviral systems, mutation-specific ASOs, and precision gene editing technologies offers a powerful, yet personalized solution to treating Usher Syndrome (Ferla et al..; Garanto; Dalkara). Employing early genetic screening can identify a patient's specific mutation and guide therapy choice, whether it is full-gene replacement for larger genes like *MYO7A,* splicing corrections for *USH2A* exon mutations, or targeted editing (Ferla et al..; AAVantgarde; ProQR Therapeutics; Slijkerman et al.). Enhancing the vector design for tissue targeting the inner ear and the retina, immune-system evasion, and high payload capacity will be essential (Muhuri et al..; Dalkara et al.). Further, integrating stem-cell regeneration or pharmacological and neuroprotective support could boost the long-term functional outcomes (Ferla et al..; ProQR Therapeutics; Dalkara et al.). As these approaches progress through clinical trials, most genuinely curative therapies are becoming imminent and can restore sensory functions rather than manage them (Ferla et al..; Stansfield; Slijkerman et al.).

Overcoming limitations & future implications

Although there is significant potential in gene therapy for treating Usher Syndrome, several obstacles need to be overcome, particularly those related to gene size, delivery, efficiency, and long-term stability, as well as access to personalized treatment. To address this problem, a multifaceted approach focused on innovation, personalization, and interdisciplinary integration is necessary. One area that needs significant improvement is the innovations in the vector delivery systems. One of the major obstacles in gene therapy for Usher Syndrome is that genes involved in specific subtypes, such as USH2A or ADRV1, are too large to be packaged in a conventional AAV vector (Jain & Daigavane). To overcome this challenge, researchers are developing dual AAV systems that can split large genes into two pieces and reassemble them once they enter the target cell (Zallocchi et al..; Jain & Daigavane). Furthermore, synthetic or engineered vectors such as Anc80 or lentiviral systems are under investigation as these have the potential to carry larger genetic payloads and target retinal or cochlear cells with greater specificity (Maeder et al.). These innovative delivery systems are being designed to reduce the immunogenicity, or immune response, while maximizing the long-term gene expression, which resolves the issues of safety and sustainability, respectively (Chen et al.). Another promising approach is using personalized gene therapy that can target a patient's specific genetic mutation. Usher Syndrome is genetically heterogeneous, and a number of genetic mutations lead to similar symptoms in different types. Using precision medicine makes it possible to create therapies that target the exact mutation in an individual's genome. Because of whole-genome sequencing breakthroughs and CRISPR-mediated editing tools, scientists are able to edit out individual point mutations in vitro, and more so in vivo, making personalized treatment more realistic rather than a high expectation (Chen et al.). In addition, antisense oligonucleotides (ASOs) are being customized to correct splicing defects in individual mutations of *USH2A* and have already shown an initial success in clinical trials(ProQR Therapeutics; Muhuri et al.). This selective approach not only

improves the chances for therapeutic efficiency but also reduces the risk of off-target effects and the heterogeneity of the response.

Lastly, for the future treatment of Usher Syndrome, it will lie in combining gene therapy with other areas of biomedical research, especially stem cell therapy and pharmacology. While gene therapy addresses the underlying cause by repairing or replacing the defective DNA, it does not reverse or damage the work already done. Stem cell therapy can potentially replace missing photoreceptors or inner ear hair cells, which offers structural and functional reconstruction (Chen et al.). Researchers can also test the medication for small molecules and neuroprotective agents, which preserve the survival of sensory cells using gene therapy. (Chen et al.). These pharmacologic therapies can be used as additives to enhance the success and duration of genetic therapies. Integrating these fields into a single therapy model can potentially halt, reverse, or prevent the progression of Usher Syndrome. With these solutions on the horizon, the future for patients with Usher Syndrome will be revolutionary. Innovative delivery systems can make treatment possible for all genetic variations, while precision medicine ensures that no one gets left out due to unusual mutations. The combination of gene therapy, stem cell biology, and pharmacological therapies may one day bring about a time when vision and hearing are not only halted in their decline but also restored to a certain extent. With sustained funding, collaboration, and clinical trial planning, these therapies can be brought to reality. If everything is done ethically and solemnly, these innovations can redefine the possibilities for what is achievable for individuals with Usher Syndrome.

Conclusion

In the final analysis, Usher Syndrome is a complicated and untreatable disorder, but gene therapy mechanisms can potentially address the root cause of Usher Syndrome. Through innovative techniques such as dual AAV vectors, antisense oligonucleotides, and CRISPR-mediated editing, researchers are moving closer to developing targeted, personalized treatments that not only manage symptoms but also address the underlying causes (Lau et al..; Gerard et. al.; Jinek et al..). Not only does this have the potential to restore the sensory function, but it also can help with long-term disease modification, especially when combined with regenerative and neuroprotective interventions. Some advances in regenerative medicine include early human studies in Japan, which transplanted induced pluripotent stem cell-derived photoreceptors into patients with retinitis pigmentosa, demonstrating that the safety and functionality are improving (Chen et. al). In addition, pre-clinical work in Australia uses viral delivery to activate endogenous retinal stem cells for photoreceptor regeneration (Wang et. al). On the pharmacological side, phase I trials of oral N-acetylcysteine in retinitis pigmentosa patients clearly showed improvements in their visual acuity and macular sensitivity, with a large-scale phase III “NAC Attack” trial going on to evaluate the long-term efficacy. When these approaches are combined with gene therapy, they may have a therapeutic benefit beyond gene correction. While challenges relating to delivery safety and accessibility continue to persist, as the biomedical field is advancing, research suggests a revolutionary future for individuals suffering from Usher Syndrome.

Acknowledgements

I would like to thank my core project mentor, Lannah, for her invaluable guidance, feedback, and support through every step of the research process. I am also extremely thankful for my showcasing mentor, Lalita, for her mentorship and insights that helped me refine my project for showcasing. I would also like to thank the Polygence Research program for providing me with different opportunities, research tools, and a platform to complete this project. Lastly, I would like to thank my parents for their support and encouragement in helping me pursue this project.

References

1. U.S. Department of Health and Human Services. *Usher Syndrome*. National Institute on Deafness and Other Communication Disorders, Dec. 2017, https://www.nidcd.nih.gov/health/usher-syndrome.
2. U.S. National Library of Medicine. *Usher Syndrome: MedlinePlus Genetics*. 17 May 2021, https://medlineplus.gov/genetics/condition/usher-syndrome/.
3. Usher Syndrome Coalition. *What Is Usher Syndrome?* n.d., https://www.usher-syndrome.org/resources/
4. Mayo Foundation for Medical Education and Research. *Gene Therapy*. Mayo Clinic, 23 Apr. 2024, https://www.mayoclinic.org/tests-procedures/gene-therapy/about/pac-20384619.
5. Genome.gov. *Gene Therapy*. n.d., https://www.genome.gov/genetics-glossary/Gene-Therapy.
6. Cantore, Alessio, et al.. "In Vivo Gene Therapy to the Liver and Nervous System: Promises and Challenges." *Frontiers in Medicine*, vol. 8, 2022, p. 774618.10.3389/fmed.2021.774618
7. Williams, David S., et al.. "Gene Therapy Approaches for Prevention of Retinal Degeneration in Usher Syndrome." *Gene Therapy*, vol. 24, no. 2, 2017, pp. 68–71. https://doi.org/10.1038/gt.2016.81.
8. U.S. Department of Health and Human Services. *Usher Syndrome*. National Eye Institute, n.d., https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/usher-syndrome.
9. U.S. National Library of Medicine. *MYO7A Gene: MedlinePlus Genetics*. 1 June 2016, https://medlineplus.gov/genetics/gene/myo7a/.
10. U.S. National Library of Medicine. *USH2A Gene: MedlinePlus Genetics*. 1 June 2016, https://medlineplus.gov/genetics/gene/ush2a/.
11. U.S. National Library of Medicine. *CLRN1 Gene: MedlinePlus Genetics*. 1 June 2016, https://medlineplus.gov/genetics/gene/clrn1/.
12. Fuster-García, Carmen, et al.. "Usher Syndrome: Genetics of a Human Ciliopathy." *International Journal of Molecular Sciences*, vol. 22, no. 13, 2021, p. 6723. https://doi.org/10.3390/ijms22136723.
13. The American Foundation for the Blind. *Orientation and Mobility*. n.d., https://www.afb.org/blog/topic/orientation-and-mobility.
14. Berson, Eliot L., et al.. "Clinical Trial of Lutein in Patients with Retinitis Pigmentosa Receiving Vitamin A." *Archives of Ophthalmology*, vol. 128, no. 4, 2010, pp. 403–11. https://doi.org/10.1001/archophthalmol.2010.32.
15. Wang, Qi, et al.. "Efficient and Stable Delivery of Multiple Genes to Fish Cells by a Modified Recombinant Baculovirus System." *International Journal of Molecular Sciences*, vol. 19, no. 12, 2018, p. 3767. https://doi.org/10.3390/ijms19123767.
16. U.S. National Library of Medicine. *What Is Gene Therapy?* 28 Feb. 2022, https://medlineplus.gov/genetics/understanding/therapy/genetherapy/.
17. Canver, Matthew C. "Evaluation of the Clinical Success of Ex Vivo and In Vivo Gene Therapy." *Journal of Young Investigators*,

2009.https://www.jyi.org/2009-january/2017/10/2/evaluation-of-the-clinical-success-of-ex-vivo-and-in-vivo-gene-therapy
18. Wang, Dali, et al.. “Adeno-Associated Virus Vector as a Platform for Gene Therapy Delivery.” *Nature Reviews Drug Discovery*, vol. 18, no. 5, 2019, pp. 358–78. https://www.nature.com/articles/s41573-019-0012-9
19. Hinderer, Christina, et al.. “Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous AAV Administration.” *Human Gene Therapy*, vol. 29, no. 3, 2018, pp. 285–98. https://doi.org/10.1089/hum.2018.015.
20. Sinn, Patrick L., et al.. “Gene Therapy Progress and Prospects: Lentiviral and Retroviral Vectors.” *Gene Therapy*, vol. 12, no. 14, 2005, pp. 1089–98. https://doi.org/10.1038/sj.gt.3302570.
21. Ginn, Samantha L., et al.. “Gene Therapy Clinical Trials Worldwide to 2012—An Update.” *The Journal of Gene Medicine*, vol. 15, no. 2, 2013, pp. 65–77.10.1002/jgm.2698
22. Hashimoto, T., et al.. “Lentiviral Gene Replacement Therapy of Retinas in a Mouse Model for Usher Syndrome Type 1B.” *Gene Therapy*, vol. 14, no. 7, 2007, pp. 584–94. https://pmc.ncbi.nlm.nih.gov/articles/PMC9307148/
23. Jinek, Martin, et al.. “A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity.” *Science*, vol. 337, no. 6096, 2012, pp. 816–21. 10.1126/science.1225829
24. Gerard, Xavier, et al.. “Antisense Oligonucleotide Therapy for Inherited Retinal Dystrophies.” *Advances in Experimental Medicine and Biology*, vol. 854, 2016, pp. 517–24. https://doi.org/10.1007/978-3-319-17121-0_69.
25. Aartsma-Rus, Annemieke, and Gert-Jan B. van Ommen. “Antisense-Mediated Exon Skipping: A Versatile Tool with Therapeutic and Research Applications.” *RNA*, vol. 13, no. 10, 2007, pp. 1609–24. https://doi.org/10.1261/rna.65360726.
26. Scalabrino, Maria L., et al.. “Late Gene Therapy Limits the Restoration of Retinal Function in a Mouse Model of Retinitis Pigmentosa.” *Nature Communications*, vol. 14, no. 1, 2023, p. 8256. https://www.nature.com/articles/s41467-023-44063-8
27. Lau, Sau C., et al.. “Dual-AAV Vector-Mediated Expression of MYO7A Improves Vestibular Function in Usher Syndrome 1B Mice.” *Molecular Therapy: Methods & Clinical Development*, vol. 30, 2023, pp. 534–45. https://doi.org/10.1016/j.omtm.2023.08.012.
28. Zallocchi, Marisa, et al.. “EIAV-Based Retinal Gene Therapy in the Shaker1 Mouse Model for Usher Syndrome Type 1B.” *PLoS ONE*, vol. 9, no. 4, 2014, e94272. https://doi.org/10.1371/journal.pone.0094272.
29. Ferla, Roberto, et al.. “Dual AAV Vectors for Usher Syndrome Type 1B: Efficacy in Primates.” *Molecular Therapy: Methods & Clinical Development*, vol. 28, 2023, pp. 396–411. https://doi.org/10.1016/j.omtm.2023.02.002.
30. AAVantgarde. “Safety Data of AAVB-081 for Usher 1B.” n.d., https://www.aavantgarde.com/en/news/aavantgarde-presents-safety-data-of-the-luce-1-study-of-aavb-081-for-rp-related-to-usher-1b/.
31. Stansfield, Nicholas. “AAVantgarde Bio Doses First Patient in Trial for Usher Syndrome Gene Therapy AAVB-081.” *CGTlive*, 23 Sept. 2024, https://www.cgtlive.com/view/aavantgarde-bio-doses-first-patient-trial-usher-syndrome-gene-therapy-aavb-081.
32. Foundation Fighting Blindness. “Sepul Bio Launches Phase 2b Clinical Trial for USH2A RNA Therapy.” 13 Dec. 2024,

https://www.fightingblindness.org/news/sepul-bio-launches-phase-2b-clinical-trial-for-ush2a-rna-therapy-1564.
33. ClinicalTrials.gov. *Study NCT06627179*. 2025, https://clinicaltrials.gov/study/NCT06627179.
34. Dulla, Kristin, et al.. "Antisense Oligonucleotide-Based Treatment of Retinitis Pigmentosa Caused by USH2A Exon 13 Mutations." *Molecular Therapy*, vol. 29, no. 8, 2021, pp. 2441–55. https://doi.org/10.1016/j.ymthe.2021.04.024.
35. ProQR Therapeutics. "Positive Results for QR-421A in Usher Syndrome." 24 Jan. 2022, https://www.proqr.com/press-releases/proqr-announces-positive-results-from-clinical-trial-of-qr-421a-in-usher-syndrome-and-plans-to-start-pivotal-trials.
36. Trapani, Ivana, et al.. "Effective Delivery of Large Genes to the Retina by Dual AAV Vectors." *EMBO Molecular Medicine*, vol. 6, no. 2, 2014, pp. 194–211. https://doi.org/10.1002/emmm.201302948.
37. Muhuri, M., et al.. "Overcoming Innate Immune Barriers That Impede AAV Gene Therapy Vectors." *Journal of Clinical Investigation (JCI)*, vol. 131, no. 1, 2021, e143780. https://doi.org/10.1172/JCI143780.
38. Slijkerman, R., et al.. "Poor Splice-Site Recognition in a Zebrafish Model for USH2A Mutations." *Zebrafish*, vol. 15, no. 6, 2018, pp. 597–609. 10.1089/zeb.2018.1613
39. Garanto, A. "RNA-Based Therapeutic Strategies for Inherited Retinal Dystrophies." *Advances in Experimental Medicine and Biology*, vol. 1185, 2019, pp. 71–77. https://doi.org/10.1007/978-3-030-27378-1_12.
40. Dalkara, Deniz, et al.. "In Vivo-Directed Evolution of a New AAV for Retinal Gene Delivery." *Science Translational Medicine*, vol. 5, no. 189, 2013, p. 189ra76. https://doi.org/10.1126/scitranslmed.3005708.
41. Jain, Rutuja, and Shreya Daigavane. "Advances and Challenges in Gene Therapy for Inherited Retinal Dystrophies." *Cureus*, vol. 16, no. 9, 2024, e69895. http
42. s://doi.org/10.7759/cureus.69895.
43. Maeder, M. L., et al.. "Development of a Gene-Editing Approach to Restore Vision Loss in Leber Congenital Amaurosis Type 10." *Nature Medicine*, vol. 25, no. 2, 2019, pp. 229–33.https://www.nature.com/articles/s41591-018-0327-9
44. Chen, K. S., et al.. "Stem Cell Therapeutics and Gene Therapy for Neurologic Disorders." *Neurotherapeutics*, vol. 21, no. 4, 2024, e00427. https://doi.org/10.1016/j.neurot.2024.e00427.